CD8A and cancer: Tumor-derived prostaglandin E2 (PGE2) programs a dysfunctional state in intratumoral type 1 conventional dendritic cells (cDC1s), disabling their ability to locally orchestrate anti-cancer CD8+ T cell responses [29].